Gennex Laboratories Ltd

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 July 2026. This shift reflects a combination of deteriorating technical indicators, a cautious financial trend outlook, and a re-evaluation of valuation metrics, despite some positive quarterly financial results. The company’s Mojo Score now stands at 46.0, signalling a Sell recommendation, marking a significant change in investor sentiment.

Gennex Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of valuation improvements, financial trends, quality assessments, and technical factors. Despite some positive quarterly financial results and an attractive valuation relative to peers, the stock’s underperformance against the broader market and mixed fundamental indicators have prompted a cautious stance from analysts.

Gennex Laboratories Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This recalibration reflects changes in key multiples such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the micro-cap pharmaceutical player as a more compelling option relative to its peers and historical averages.

Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Gennex Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 16 June 2026, is driven by a combination of enhanced technical trends, solid quarterly financial results, attractive valuation metrics, and a stable quality profile, signalling a cautious but optimistic outlook for this micro-cap pharmaceutical player.

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This revision reflects a combination of deteriorating technical indicators, valuation concerns, and underwhelming recent market performance despite some positive financial trends.

Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion.

Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to peers and historical averages.